Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 47%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc. is positioned favorably due to its innovative hydrogel platform technology, which provides a significant advantage over traditional eye-drop therapies in treating ophthalmic diseases. The company’s leading product, Dextenza, has showcased consistent annual revenue growth since its market introduction in July 2019, suggesting strong commercial viability. Additionally, the anticipated readout of Axpaxli's SOL-1 trial in 1Q26 is expected to reinforce market confidence and may unlock further growth potential in a rapidly expanding anti-VEGF treatment sector projected to reach approximately $18 billion by 2028.

Bears say

Ocular Therapeutix Inc. is experiencing significant sales declines, with a reported reduction of 68% year-over-year in revenues, primarily due to increasing competition from biosimilars and new entrants in the ophthalmic market such as Eylea and Vabysmo. The company's revenue for its lead product, Dextenza, while meeting management’s guidance at $17 million for Q4 2024, is still slightly below the consensus estimates, indicating challenges in maintaining market performance. Additionally, the postponement of pivotal data for the pipeline product Axpaxli to Q1 2026 raises concerns about the potential for clinical trial success, further jeopardizing the company’s financial outlook.

Ocular Therapeutix (OCUL) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 47% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 19 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.